Waters says the deal for CDMS developer Megadalton Solutions, which it calls tantamount to an acquisition, will grow its mass spec capabilities to analyzing proteins and protein complexes as large as 108 Daltons (Da)—compared with the 101 to 106 range offered by conventional mass spec. Waters president and CEO Udit Batra, PhD, said Megadalton’s CDMS will stretch mass spec analysis beyond the COVID-19 spike protein, into virus-like particles, as well as adeno-associated viruses (AAVs) and larger adenoviruses . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge